These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17353665)

  • 41. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pleiotropic effects and cholesterol-lowering therapy.
    Shaw SM; Fildes JE; Yonan N; Williams SG
    Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of intensive statin therapy in the elderly.
    Maroo BP; Lavie CJ; Milani RV
    Am J Geriatr Cardiol; 2008; 17(2):92-100. PubMed ID: 18326948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of statin therapy in patients with preexisting liver disease.
    Onofrei MD; Butler KL; Fuke DC; Miller HB
    Pharmacotherapy; 2008 Apr; 28(4):522-9. PubMed ID: 18363535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
    Kinlay S
    J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The safety of niacin in the US Food and Drug Administration adverse event reporting database.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Statin-drug interactions: not a class effect.
    Frishman WH; Horn J
    Cardiol Rev; 2008; 16(4):205-12. PubMed ID: 18562811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenetics: the outlook for genetic testing in statin therapy.
    Chasman DI; Ridker PM
    Nat Clin Pract Cardiovasc Med; 2005 Jan; 2(1):2-3. PubMed ID: 16265332
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacogenetics of statins therapy.
    Puccetti L; Acampa M; Auteri A
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):228-36. PubMed ID: 18221122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The pharmacogenomics of statins.
    Gelissen IC; McLachlan AJ
    Pharmacol Res; 2014 Oct; 88():99-106. PubMed ID: 24365577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transporter pharmacogenetics and statin toxicity.
    Niemi M
    Clin Pharmacol Ther; 2010 Jan; 87(1):130-3. PubMed ID: 19890253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bile acid sequestrants: their use in combination with other lipid-lowering agents.
    Mandeville WH; Arbeeny C
    IDrugs; 1999 Mar; 2(3):237-42. PubMed ID: 16160934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety.
    Shatnawi A; Kamran Z; Al-Share Q
    Per Med; 2023 Jan; 20(1):65-86. PubMed ID: 36416179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.